Bioverge

EnClear Therapies develops device-based therapies for treating neurodegenerative diseases by removing toxic proteins from cerebrospinal fluid. Its initial targets are Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). Incorporated in 2018, the company is based in Newburyport, Massachusetts.

UberDoc, established in 2016 and based in Boston, is a digital platform that facilitates direct access to medical specialists for patients seeking urgent care. The company offers a transparent pricing structure, allowing patients to connect with qualified doctors without the need for referrals or insurance paperwork. By leveraging advanced mobile technology, UberDoc simplifies the appointment process, enabling users to search for specialists, book appointments, and pay using various methods including Health Savings Accounts and credit cards. A nominal transaction fee is charged to secure appointments, with additional fees applicable post-consultation. Founded by Paula Muto, a recognized vascular and general surgeon, UberDoc has rapidly expanded its reach, enrolling thousands of doctors across the United States and serving patients daily. The platform has earned a reputation as a leader in the digital health community, participating in numerous industry conferences.

My Diabetes Tutor specializes in telehealth services for diabetes education. Accredited by the American Association of Diabetes Educators, it provides high-quality, accessible education to individuals with diabetes, focusing on prevention and self-management.

Modulo Bio simulates the neuroimmune system to identify medication candidates that target microglia, and the company combines stem cell biology, neuroscience, software, automation, and artificial intelligence to create neuroimmune microenvironments from stem cells and to manipulate and measure the neuroimmune system in cell models and patient samples, enabling researchers to discover new treatments for neurodegenerative diseases.

Jelikalite develops medical equipment for children with autism spectrum disorders, focusing on non-invasive approaches to support brain health. The company has created a therapeutic wearable device that combines near-infrared light, sensors, and a machine-learning personalization system to deliver non-invasive brain stimulation. Designed for home-based use without a therapist's physical presence, the device seeks to improve communication, responsiveness, and social interaction in children with autism.

Eigen Therapeutics is a biotechnology company dedicated to advancing cancer treatment through the development of innovative therapies. It specializes in "priming" therapies that enhance the effectiveness of targeted treatments by addressing cancer heterogeneity, which makes cancer cells more susceptible to therapeutic interventions while simultaneously protecting healthy cells. Eigen is creating a high-throughput discovery platform that integrates proprietary machine learning algorithms to identify novel drug classes and therapeutic approaches capable of altering a cell’s state to increase vulnerability to treatments. This platform combines biology and engineering, utilizing in-house developed robotic systems, laboratory operations software, and machine learning analysis pipelines. The company's mission focuses on improving patient outcomes by providing novel combination therapeutics that enhance efficacy and reduce toxicity in cancer care, ultimately aiming to meet significant medical needs in oncology.

Founded in 2017 as a spin‑out from GigaGen, GigaMune is a biotechnology company focused on next‑generation T cell therapies. It combines deep insights into T cell responses to tumors with massively parallel T cell receptor discovery to identify novel therapeutic targets. The company also develops genome‑edited cancer cell therapies, offering technology that supports database‑scale sequence searches, high‑throughput screening of anti‑tumor payloads, and the use of engineered viruses for payload delivery. These tools enable the rapid development of effective treatments for various cancers.

Notable Labs, Inc. is a clinical-stage company that specializes in personalized lab testing services for cancer patients, particularly those with brain cancer. Founded in 2014 and based in Foster City, California, the company utilizes its proprietary Predictive Precision Medicines Platform to conduct drug combination experiments on patients' tumors. This platform allows Notable Labs to simulate cancer treatments and predict patient responses to specific therapies, enabling healthcare providers to prioritize combinations of FDA-approved treatments that can be prescribed without the need for clinical trials. By providing detailed reports to physicians, Notable Labs aims to enhance treatment efficacy and expedite therapeutic development for patients.

Foresight Mental Health is a technology-enabled psychiatry and therapy services company that directly employs psychiatrists, therapists, and psychiatric nurse practitioners to treat patients in its clinics. The company develops technology in collaboration with its providers, leveraging software and biomedical engineering to enhance care. Through a network of clinics, it offers a broad range of mental health treatments and wellness services and maintains patient profiles and a repository of scientific research and clinical information, including genetic profiles, comprehensive symptom profiles, and brain-chemical balance estimates to inform personalized care.

Octant Bio is a company focused on developing synthetic technology to enhance health and treat diseases. The firm employs synthetic biology, genome engineering, next-generation sequencing, and computational tools to measure the activity of thousands of receptor pathways in human cells simultaneously. This approach allows scientists to use machine learning methods to engineer small molecules that can interact with multiple receptors, offering new potential for treating complex diseases.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on redefining psychiatry through the integration of patient neurobiology into the drug development process. Utilizing an AI-enabled biomarker platform, the company combines diverse information about patients' brain activity and behavior to create personalized and effective treatment options. Alto Neuroscience is developing several clinical assets, including ALTO-100, ALTO-202, ALTO-101, and ALTO-300, primarily targeting depressive disorders and schizophrenia, identified through independent brain-based biomarkers. By moving away from traditional trial-and-error methods, the company aims to align its innovative therapies with the specific needs of patients, ultimately improving the management of mental health conditions.

Founded in 2016, Bionaut Labs specializes in developing intra-tissue navigation platforms using micro-robots for precise anatomical targeting. Its innovative technology enables remote-controlled delivery of therapeutics to challenging clinical settings, revolutionizing the treatment of central nervous system disorders and other diseases.

Eigen Therapeutics is a biotechnology company dedicated to advancing cancer treatment through the development of innovative therapies. It specializes in "priming" therapies that enhance the effectiveness of targeted treatments by addressing cancer heterogeneity, which makes cancer cells more susceptible to therapeutic interventions while simultaneously protecting healthy cells. Eigen is creating a high-throughput discovery platform that integrates proprietary machine learning algorithms to identify novel drug classes and therapeutic approaches capable of altering a cell’s state to increase vulnerability to treatments. This platform combines biology and engineering, utilizing in-house developed robotic systems, laboratory operations software, and machine learning analysis pipelines. The company's mission focuses on improving patient outcomes by providing novel combination therapeutics that enhance efficacy and reduce toxicity in cancer care, ultimately aiming to meet significant medical needs in oncology.

Circularis Biotechnologies, Inc. is a biotechnology company founded in 2014 and headquartered in Oakland, California. The company specializes in developing innovative methods to regulate gene expression, which enhances the production yields of biotherapeutics. Circularis offers a range of products, including RACRE Variant Libraries, hCMV Variant Library, Protein expression with CMV promoters, and T7 Variant Library. In addition, it provides various services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. Through its advanced technologies and services, Circularis aims to improve the efficiency and effectiveness of biotherapeutic production.

Ochre Bio is a biotechnology company founded in 2019 and headquartered in Oxford, United Kingdom. The firm focuses on developing genomic medicines that rejuvenate donor livers before transplantation, aiming to expand the supply of healthy organs for patients. By using genomics to identify and silence over‑active genes that drive liver disease, Ochre Bio tests novel RNA‑based therapies directly in discarded donor livers maintained on machine‑based perfusion systems. This approach allows the company to evaluate treatments in a human organ context, reducing complications such as cirrhosis and improving transplant outcomes. With more than fifteen years of liver genomics research experience, Ochre Bio leverages deep phenotyping and advanced therapeutic modalities to create a pipeline of medicines for liver and liver‑mediated conditions.

NutriSense, established in 2019 and headquartered in Chicago, Illinois, specializes in AI-driven corporate wellness programs. The company offers a comprehensive solution comprising continuous glucose monitoring (CGM) devices, a tracking app for diet management, and personalized consultations with registered dietitians. NutriSense leverages machine learning technology to provide real-time blood glucose level monitoring and tailored nutrition insights, aiming to empower individuals to achieve their health goals.

BioROSA Technologies Inc. is a biotechnology company focused on developing diagnostic tools for Autism Spectrum Disorders (ASD). Founded in 2018 and headquartered in Belmont, Massachusetts, the company specializes in creating biologically-based blood tests that assist clinicians in identifying individuals at risk for ASD. By utilizing machine learning to analyze biological data, BioROSA Technologies aims to provide reliable and accurate diagnoses, facilitating early detection and timely treatment. Additionally, the company's technology supports therapeutic trials by evaluating pharmacodynamics and patient stratification, thereby enhancing the overall standard of care for ASD.

Juno Diagnostics is a San Diego-based health technology company developing noninvasive, cell-free DNA-based prenatal testing and other genetic testing tools. The company focuses on creating simple, cost-effective devices to enable point-of-need and in-home genetic testing, reducing the cost, lead times, and need for phlebotomy associated with traditional testing. Its work spans applications in fetal screening, epigenetics, inherited diseases, and cancer diagnostics, aiming to democratize access to high-value genetic information for patients and physicians.

HepaTx Corporation, founded in 2015 and headquartered in Palo Alto, California, specializes in developing regenerative medicine solutions for liver diseases. The company focuses on creating innovative therapies that address the urgent need for improved treatments for life-threatening liver conditions. Utilizing technology developed at Stanford University, HepaTx efficiently produces hepatocytes for therapeutic applications, aiming to replace lost liver function in patients with end-stage liver disease. This approach has the potential to reduce the need for costly and complex whole organ transplants, offering a novel and cost-effective alternative for patients previously deemed untreatable.

Juno Diagnostics is a San Diego-based health technology company developing noninvasive, cell-free DNA-based prenatal testing and other genetic testing tools. The company focuses on creating simple, cost-effective devices to enable point-of-need and in-home genetic testing, reducing the cost, lead times, and need for phlebotomy associated with traditional testing. Its work spans applications in fetal screening, epigenetics, inherited diseases, and cancer diagnostics, aiming to democratize access to high-value genetic information for patients and physicians.

Based in Boston's biotech hub, Elucid improves cardiovascular diagnostic imaging via machine learning. Its flagship product, ElucidVivo, is the first FDA-cleared software for evaluating plaque vulnerability from a single CT scan to inform risk assessment and treatment selection.

IVIVA Medical, Inc. is a biotechnology company based in Beverly, Massachusetts, focused on developing innovative therapies for end-stage renal disease (ESRD). Founded in 2013, the company aims to address the critical shortage of donor organs by creating autologous tissue constructs that provide alternative treatments for patients suffering from this condition, which affects over 500,000 individuals in the United States. IVIVA Medical leverages advanced technologies in tissue engineering, 3D additive manufacturing, and stem cell biology to create bioartificial platforms and systems. These platforms not only facilitate therapeutic applications but also serve as essential building blocks for the next generation of engineered, functionalized tissues, positioning IVIVA Medical at the forefront of regenerative medicine and enhancing the capacity of medical professionals to manage end-stage kidney disease.

Ancilia Biosciences is a biotechnology company focused on developing engineered bacterial therapies aimed at treating diseases associated with the microbiome. The company specializes in creating virus-resistant live bacterial products that modulate the human microbiome, specifically targeting the viral components of the gut microbiome. By concentrating on enhancing healthy gut bacteria and their predatory phages, Ancilia develops therapeutic strains that can effectively combat chronic diseases in the fields of immunology and oncology. Additionally, the company is pioneering a new class of live biotherapeutics that allow for the precise targeting of phages or viruses known to induce lysis, thereby advancing treatment options in microbiome-related health conditions.

Repair Biotechnologies, Inc. is a biotechnology company founded in 2018 and based in Syracuse, New York. The company focuses on developing innovative therapies aimed at reversing the progression of age-related conditions such as immunosenescence and atherosclerosis. Utilizing a cholesterol-degrading platform, Repair Biotechnologies creates treatments that address conditions driven by excess or modified cholesterol, including atherosclerosis and familial hypercholesterolemia. Their approach centers on gene therapy and recombinant protein strategies, designed to be safe and well-tolerated, allowing patients to target the underlying causes of diseases associated with cholesterol accumulation.

Octagon Therapeutics is a preclinical-stage biopharmaceutical company developing targeted immunomodulator medicines for chronic autoimmune and inflammatory diseases. Incorporated in 2016, the company is based in Cambridge, Massachusetts.

Circularis Biotechnologies, Inc. is a biotechnology company founded in 2014 and headquartered in Oakland, California. The company specializes in developing innovative methods to regulate gene expression, which enhances the production yields of biotherapeutics. Circularis offers a range of products, including RACRE Variant Libraries, hCMV Variant Library, Protein expression with CMV promoters, and T7 Variant Library. In addition, it provides various services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. Through its advanced technologies and services, Circularis aims to improve the efficiency and effectiveness of biotherapeutic production.

Volumetric, Inc. is an advanced biomaterials and biofabrication company based in Houston, Texas, established in 2014. It specializes in developing a 3D bioprinting platform designed to create vascularized human tissue, which can be utilized in various applications such as life sciences, drug discovery, and medical devices. The company offers bioprinters and bioinks that aim to facilitate innovations in biomaterials, cancer research, and the potential replacement of human organs. By focusing on creating materials embedded with living cells, Volumetric is at the forefront of integrating cutting-edge technology into healthcare solutions.

Pragma Bio is a biotechnology company that uses microbiome-based approaches to discover therapies for cancer and autoimmune diseases, combining genomic sequencing, artificial intelligence, and synthetic biology to identify biomarkers and develop therapeutics through a data-driven platform that aggregates public and private data to build a microbiome database and reveal connections across microbial and clinical data. The company pursues small-molecule discovery from human-associated bacteria, focusing on the gut-immune axis, and aims to deliver health-indicative molecules with robust safety profiles, while the platform supports risk stratification and outcome prediction for patients by leveraging real-world data. Pragma Bio was founded in 2018 in Millbrae, California by Peter McCaffrey, Kovi Bessoff, Ayin Vala and Kareem Barghouti.

Pragma Bio is a biotechnology company that uses microbiome-based approaches to discover therapies for cancer and autoimmune diseases, combining genomic sequencing, artificial intelligence, and synthetic biology to identify biomarkers and develop therapeutics through a data-driven platform that aggregates public and private data to build a microbiome database and reveal connections across microbial and clinical data. The company pursues small-molecule discovery from human-associated bacteria, focusing on the gut-immune axis, and aims to deliver health-indicative molecules with robust safety profiles, while the platform supports risk stratification and outcome prediction for patients by leveraging real-world data. Pragma Bio was founded in 2018 in Millbrae, California by Peter McCaffrey, Kovi Bessoff, Ayin Vala and Kareem Barghouti.

Contraline, Inc. is a biotechnology company based in Charlottesville, Virginia, focused on developing innovative male birth control solutions. The company is pioneering the first long-lasting, non-hormonal, and reversible contraceptive for men. Its primary product, Echo-V, is an ultrasound-visible polymer solution that is injected into the vas deferens, forming a polymer hydrogel device. This device functions as a semi-permeable membrane, effectively blocking sperm while allowing bodily fluids to pass through. Contraline also offers Vasintomy, a non-surgical procedure for the insertion of Echo-V, providing a cost-effective and accessible approach to male contraception. Incorporated in 2015, Contraline aims to transform the landscape of reproductive health for men.

RockStep Solutions specializes in cloud-based informatics platforms for managing data and operations in drug discovery. Its flagship product, Climb, addresses data chaos and operational inefficiencies, enhancing return on investment (ROI) for pharmaceutical research across tier-1 pharma, biotechs, contract research organizations (CROS), and academia.

Excision BioTherapeutics Inc. is a life science company based in Philadelphia, Pennsylvania, established in 2015. The company is dedicated to the development and commercialization of gene editing therapeutics aimed at treating life-threatening diseases caused by neurotropic viruses. Utilizing CRISPR-based technology, Excision BioTherapeutics focuses on creating advanced gene-editing medicines that can eradicate or disrupt viral genes in human patients. The company's mission is to advance these therapeutics into safe and effective treatments, significantly improving the lives of individuals affected by viral infections globally.

EnClear Therapies develops device-based therapies for treating neurodegenerative diseases by removing toxic proteins from cerebrospinal fluid. Its initial targets are Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). Incorporated in 2018, the company is based in Newburyport, Massachusetts.

Foresight Mental Health is a technology-enabled psychiatry and therapy services company that directly employs psychiatrists, therapists, and psychiatric nurse practitioners to treat patients in its clinics. The company develops technology in collaboration with its providers, leveraging software and biomedical engineering to enhance care. Through a network of clinics, it offers a broad range of mental health treatments and wellness services and maintains patient profiles and a repository of scientific research and clinical information, including genetic profiles, comprehensive symptom profiles, and brain-chemical balance estimates to inform personalized care.

Ombre specializes in microbiome testing kits that offer personalized probiotics based on individual test results. Their subscription-based service provides actionable insights into gut health, aiming to prevent chronic diseases such as obesity, cystic fibrosis, and Alzheimer's.

Suggestic, Inc. is a San Francisco-based company founded in 2014 that specializes in automated and personalized lifestyle and nutrition coaching. Its platform leverages proprietary artificial intelligence to create tailored diet plans that cater to users' individual goals, dietary preferences, and restrictions. The application facilitates precision eating by offering personalized meal plans, smart shopping lists, recipe suggestions, and restaurant recommendations. By encoding dietary programs as rulesets, Suggestic enables health-related organizations to efficiently build and deliver customized nutrition programs through white label solutions or direct API integration. The platform also supports data acquisition from users through assessments and lab tests, allowing it to provide relevant food recommendations that assist individuals in weight management, enhancing vitality, and preventing or reversing chronic diseases.

Ombre specializes in microbiome testing kits that offer personalized probiotics based on individual test results. Their subscription-based service provides actionable insights into gut health, aiming to prevent chronic diseases such as obesity, cystic fibrosis, and Alzheimer's.

Intelligent Implants is a bioelectronics company developing an implantable electrical stimulation platform that uses wireless devices to stimulate, steer, and monitor bone growth and tissue recovery. The company designs electrotherapeutic medical devices intended to treat diseases and accelerate healing in bone and other tissues. Its implants enable healthcare providers to control and monitor treatment, supporting decision making in patient care. By integrating data, engineering and medicine, Intelligent Implants aims to bring active, connected medical devices to clinical practice, improving outcomes for individuals with bone conditions and related injuries.

Leucadia Therapeutics Inc. is a privately-held, pre-clinical stage company based in Riverside, California, dedicated to the prevention and treatment of Alzheimer's disease. The company manufactures an implantable device called Arethusta, which restores cerebrospinal fluid (CSF) flow across the cribriform plate. This restoration improves the clearance of toxic metabolites from the brain's earliest affected regions, potentially preventing the onset of Alzheimer's disease. Additionally, Leucadia is developing a diagnostic algorithm that utilizes big data to assess Alzheimer's disease risk, further enhancing its capabilities in addressing this complex condition.

OccamzRazor develops an AI-powered platform for neuroscience drug discovery and development. It combines machine learning with first-in-class biological techniques to integrate unstructured biomedical text with structured data such as genomics, proteomics and phenomics, generating stronger hypotheses for target identification and drug repurposing. The company's technology analyzes diverse data sources to construct a comprehensive knowledge graph that captures all known information about Parkinson's disease, enabling clinicians and researchers to derive downstream therapeutic insights and to guide strategic drug development.

EnClear Therapies develops device-based therapies for treating neurodegenerative diseases by removing toxic proteins from cerebrospinal fluid. Its initial targets are Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). Incorporated in 2018, the company is based in Newburyport, Massachusetts.

Blue Mesa Health Inc. is a digital therapeutics company focused on diabetes prevention through its innovative platform, Transform. Founded in 2015 and based in New York, the company provides a comprehensive solution that combines health coaching, behavioral psychology, and technology to help individuals reverse prediabetes and manage their health. Transform offers a weight loss program and weekly lessons, delivering evidence-based behavioral interventions in a flexible format. The company's mission extends beyond the United States, as it has launched its services in Latin America and the Middle East, aiming to become a global leader in culturally diverse, technology-driven health solutions. Blue Mesa Health operates as a subsidiary of Virgin Pulse, Inc.

Blue Mesa Health Inc. is a digital therapeutics company focused on diabetes prevention through its innovative platform, Transform. Founded in 2015 and based in New York, the company provides a comprehensive solution that combines health coaching, behavioral psychology, and technology to help individuals reverse prediabetes and manage their health. Transform offers a weight loss program and weekly lessons, delivering evidence-based behavioral interventions in a flexible format. The company's mission extends beyond the United States, as it has launched its services in Latin America and the Middle East, aiming to become a global leader in culturally diverse, technology-driven health solutions. Blue Mesa Health operates as a subsidiary of Virgin Pulse, Inc.

Ligandal develops therapeutic nanotechnologies for precise delivery of genetic materials and gene-specific payloads. Founded in 2013, it specializes in non-viral nano-carriers to treat gene-related diseases, with initial focus on hematology, immuno-oncology, and infectious disease.

Notable Labs, Inc. is a clinical-stage company that specializes in personalized lab testing services for cancer patients, particularly those with brain cancer. Founded in 2014 and based in Foster City, California, the company utilizes its proprietary Predictive Precision Medicines Platform to conduct drug combination experiments on patients' tumors. This platform allows Notable Labs to simulate cancer treatments and predict patient responses to specific therapies, enabling healthcare providers to prioritize combinations of FDA-approved treatments that can be prescribed without the need for clinical trials. By providing detailed reports to physicians, Notable Labs aims to enhance treatment efficacy and expedite therapeutic development for patients.

Echo is a provider of am automated microscope intended for biological research and pathologies. The company's product provides features like inverted images, cell counting, phase contrast, brightfield and fluorescence, enabling customers to have accurate images at a lower cost.

CrowdMed, Inc. is a San Francisco-based company that leverages a prediction market technology to assist in diagnosing complex medical conditions. Founded in 2012, CrowdMed aims to provide patients with streamlined access to diagnostic information for their undiagnosed and chronic symptoms. The company's platform connects patients with a diverse network of medical detectives, including licensed physicians, medical students, and other healthcare professionals, who collaborate to generate diagnostic suggestions. By harnessing the collective intelligence of these experts, CrowdMed offers a collaborative solution for individuals facing unresolved medical issues, ultimately aiming to reduce healthcare costs while maintaining quality care. The platform is designed to empower patients by providing them with insightful answers to their medical challenges through the speed and convenience of online interaction.

Echo is a provider of am automated microscope intended for biological research and pathologies. The company's product provides features like inverted images, cell counting, phase contrast, brightfield and fluorescence, enabling customers to have accurate images at a lower cost.

Echo, we believe health is about people, not pills. That’s why we’ve created a new kind of pharmacy. One that comes to you, not the other way around. We start with being brilliant at fulfilling prescriptions because getting people taking the right medicine is the first step in staying well. But there’s more we can do. It’s not just patients we support, its partners. Together with other like-minded pharmacies, GPs and prescribing services we deliver even more positive experiences. Ultimately, we want to help patients understand and do more for themselves, so together they can make the right decisions with their GPs. And when it comes time to improve our health, we all know more Technology should make the future of health care more human. So ours comes packed with care.

Notable Labs, Inc. is a clinical-stage company that specializes in personalized lab testing services for cancer patients, particularly those with brain cancer. Founded in 2014 and based in Foster City, California, the company utilizes its proprietary Predictive Precision Medicines Platform to conduct drug combination experiments on patients' tumors. This platform allows Notable Labs to simulate cancer treatments and predict patient responses to specific therapies, enabling healthcare providers to prioritize combinations of FDA-approved treatments that can be prescribed without the need for clinical trials. By providing detailed reports to physicians, Notable Labs aims to enhance treatment efficacy and expedite therapeutic development for patients.